<?xml version="1.0" encoding="UTF-8"?>
<p>On 30 December 2019, a cluster of 27 pneumonia cases (including 7 severe cases) of unknown origin emerged in Wuhan (Hubei, China) and were reported to the National Health Commission of China (
 <xref rid="B1" ref-type="bibr">1</xref>). In the early stages of this pneumonia, patients developed severe acute respiratory infection symptoms, and some patients rapidly developed acute respiratory distress syndrome (
 <xref rid="B2" ref-type="bibr">2</xref>). Real-time PCR (RT-PCR) and deep sequencing analysis of lower respiratory tract samples identified a novel human coronavirus (HCoV), now called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) (
 <xref rid="B3" ref-type="bibr">3</xref>
 <xref ref-type="bibr" rid="B4">–</xref>
 <xref rid="B5" ref-type="bibr">5</xref>). By the end of January 2020, nearly 50,000 confirmed cases were reported in China, and the first confirmed cases were reported in Thailand, Nepal, Republic of Korea, the United States, Singapore, France, Vietnam, Canada, Australia, Malaysia, Germany, The United Arab Emirates (UAE), Finland, Italy, Cambodia, Sri Lanka, the Russian Federation, Spain, Sweden, India, and the Philippines. Among the patients with confirmed cases, most (80%) were aged 30 to 80 years and had mild infections. The fatality rate was around 2% (
 <xref rid="B6" ref-type="bibr">6</xref>).
</p>
